Investors Buy High Volume of Call Options on Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) saw some unusual options trading activity on Wednesday. Traders bought 51,813 call options on the company. This is an increase of 264% compared to the average daily volume of 14,225 call options.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. TD Cowen reaffirmed a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday. Finally, Wolfe Research assumed coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Stock Down 6.1 %

Shares of NASDAQ:TEM opened at $64.99 on Friday. Tempus AI has a twelve month low of $22.89 and a twelve month high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business has a fifty day moving average of $44.36 and a 200-day moving average of $48.84.

Insider Buying and Selling at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 476,209 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total value of $23,734,256.56. Following the transaction, the chief executive officer now owns 6,502,643 shares in the company, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $62.50, for a total value of $1,250,000.00. Following the completion of the transaction, the chief operating officer now owns 962,442 shares in the company, valued at $60,152,625. This represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,058,072 shares of company stock valued at $90,719,375.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC acquired a new position in Tempus AI during the 4th quarter worth approximately $67,000. IFP Advisors Inc acquired a new position in Tempus AI during the 4th quarter worth approximately $76,000. US Bancorp DE acquired a new position in Tempus AI during the 4th quarter worth approximately $80,000. Finally, Vestor Capital LLC acquired a new position in Tempus AI during the 3rd quarter worth approximately $153,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.